Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 11/20 | 0.38 |
| ▸ | IGF1R | P08069 | 9/20 | 0.38 |
| ▸ | KDR | P35968 | 9/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 2/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4010323 | 0.88 | FGFR1 (0.43) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL5109348 | 0.84 | IGF1R (0.57) | FGFR1IGF1RKDRINSR | |
| SCHEMBL4006530 | 0.82 | FGFR1 (0.43) | FGFR1IGF1RKDRINSRFGFR2 | |
| SCHEMBL4007933 | 0.82 | FGFR1 (0.37) | FGFR1IGF1RKDRINSR | |
| SCHEMBL5096788 | 0.82 | IGF1R (0.34) | FGFR1IGF1RKDRINSR | |
| SCHEMBL4014995 | 0.79 | FGFR1 (0.43) | FGFR1IGF1RKDRINSR | |
| SCHEMBL5103645 | 0.78 | FGFR1 (0.38) | FGFR1IGF1RKDRINSR | |
| SCHEMBL5096876 | 0.76 | FGFR1 (0.40) | FGFR1IGF1RKDRINSR | |
| SCHEMBL5110696 | 0.74 | CYP4F2 (0.40) | FGFR1IGF1RKDRGRM5 | |
| SCHEMBL4010331 | 0.72 | IGF1R (0.64) | FGFR1IGF1RKDRINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | FGFR1 1428/4885IGF1R 3217/4885KDR 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.